|
US10736872B1
|
|
Pharmaceutical mixture to treat statin induced vascular calcification
|
|
US10610474B1
|
|
Antibacterial and antifungal dental health formulation
|
|
US10463590B1
|
|
Antiplaque and dental health oral formulation
|
|
US10568866B1
|
|
Composition and its use for increasing innate immune health
|
|
US10238619B1
|
|
Composition and method of using the same
|
|
US2017348280A1
|
|
Counteracting the inhibition of collagen synthesis by select calcium and sodium channel blockers using ascorbic acid and ascorbyl palmitate
|
|
WO2016138327A1
|
|
Method and system for a positional display of nutrients and their effect on the human body
|
|
WO2016126282A1
|
|
Method and system for real time visualization of individual health condition on a mobile device
|
|
US2015149217A1
|
|
Method and system for real time visualization of individual health condition on a mobile device
|
|
US2016106777A1
|
|
Novel composition method of using the same for the treatment of lyme disease
|
|
CA2877298A1
|
|
Transgenic mouse expressing human lipoprotein (a) with disabled vitamin c gene and its use as a disease treatment model
|
|
WO2016057050A1
|
|
Transgenic mouse expressing human lipoprotein (a) with disabled vitamin c gene and its use as a disease treatment model
|
|
US2015074837A1
|
|
Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
|
|
US2014017267A1
|
|
Metalloproteinase oligopeptides and their therapeutic use
|
|
US2013040274A1
|
|
Integrated interactive system and method for visualizing human physiology, disease, treatment options and use
|
|
US2012321656A1
|
|
Oligopeptides and their use for treating infectious diseases
|
|
US2013040273A1
|
|
Integrated multimedia tool system and method to explore and study the virtual human body
|
|
US8003110B1
|
|
Metalloproteinase oligopeptides and their therapeutic use
|
|
WO9119488A1
|
|
REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
|
|
US5278189A
|
|
Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
|
